MedTrace Logo

Docetaxel+Oxali+/-Cetux Met Gastric/GEJ

NCT00517829 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2016-11-28

Study results available
· View outcomes & findings →

Summary

The purpose of this research study is to find out what effects (good and bad) docetaxel, oxaliplatin, and cetuximab have on gastric or GEJ cancer.

Conditions

  • Gastric Cancer Adenocarcinoma Metastatic

Interventions

DRUG

Docetaxel

Taxotere 60 mg/m2 as an intravenous (IV) infusion over 1 hour

DRUG

cetuximab

ERBITUX 400 mg/m2 IV over 120 minutes (first dose only), all other doses are 250 mg/m2 over 60 minutes.

DRUG

oxaliplatin

Eloxatin 130 mg/m2 IV over 2 hours

Sponsors & Collaborators

Principal Investigators

  • Donald A Richards, MD · US Oncology Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2012-04-30
Completion
2012-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00517829 on ClinicalTrials.gov